Neuroblastoma Patient Regains Mobility After Therapy
A 10-year-old patient regained leg movement following targeted radiation treatment for neuroblastoma in Fort Worth.
Updated on Oct. 23, 2026 in Cancer
Ten-year-old neuroblastoma patient Ember Harguess has regained movement in her legs following MIBG therapy at Cook Children's Medical Center. Recent medical scans confirm the young patient's tumor is responding well to the radiation treatment.
Why it matters
The family transferred care to the Fort Worth facility after Harguess lost the ability to move her legs during her battle with neuroblastoma. This progress marks a significant milestone in her recovery following the targeted radiation intervention.
Clinical observations at Cook Children's Medical Center show positive patient progress, specifically the restoration of motor function in the legs following MIBG therapy. The long-term efficacy and specific treatment roadmap for this case remain under clinical investigation.
The players
Ember Harguess
A 10-year-old patient undergoing treatment for neuroblastoma.
Cook Children's Medical Center
A Fort Worth facility providing specialized pediatric cancer care.
The details
MIBG therapy involves injecting radioactive iodine-131 into the body to deliver targeted radiation directly to neuroblastoma cells. This approach aims to destroy cancerous tissue while minimizing damage to surrounding healthy cells. Harguess, who resides in Alexander, Arkansas, moved to the Fort Worth, Texas area specifically to access this specialized treatment after experiencing neurological symptoms.
Timeline
Late 2024: Ember Harguess began her neuroblastoma treatment.
October 2025: Reporters interviewed the Harguess family regarding the case.
October 23, 2026: News report confirmed positive treatment progress.
November 23, 2026: Ember Harguess will celebrate her 11th birthday.
Health Landscape
This case aligns with the standard use of MIBG therapy as a targeted treatment for high-risk neuroblastoma. The clinical focus remains on utilizing internal radiation to address tumor growth while managing severe neurological side effects.
Families managing a neuroblastoma diagnosis should maintain open communication with their oncology team regarding any loss of mobility or new neurological symptoms. Such developments in pediatric care are always worth discussing with your primary physician or specialist.
The takeaway
Targeted therapies like MIBG continue to be a vital component of neuroblastoma treatment strategies. Parents and caregivers should closely monitor patients for changes in physical function and report them to clinical teams immediately.
Further reading
For more information on pediatric oncology and related care, visit Cancer.
Source note: This article includes information reported by KLRT - FOX16.com.
